Mylan Says Novartis' Lotrel Patent Invalid

Law360, New York (November 7, 2007, 12:00 AM EST) -- Mylan Pharmaceuticals Inc. has struck back at Novartis International AG, claiming that the patent Novartis asserted when it sued Mylan over the hypertension drug Lotrel is invalid.

Mylan filed its answer and counterclaim Tuesday in the U.S. District Court for the District of New Jersey. It joined other generics makers, like Par Pharmaceuticals and Lupin Ltd., that have claimed the Lotrel patent is not valid.

Novartis sued Mylan on Oct. 11 over Mylan's bid to enter Lotrel's billion-dollar annual market. Novartis asserted U.S. Patent Number 6,162,802,...
To view the full article, register now.